Skip to main content
. Author manuscript; available in PMC: 2020 May 15.
Published in final edited form as: Science. 2020 Apr 10;368(6487):eaaw5473. doi: 10.1126/science.aaw5473

Fig. 2. Accumulation of somatically acquired mutations changes tumor biology and causes metabolic liabilities to evolve.

Fig. 2.

KRAS mutations initiate tumorigenesis in the lung, driving nutrient uptake and anabolism. Mutation of STK11 increases key aspects of aggressive tumor biology, including metastatic efficiency and therapy resistance, but increases sensitivity to some metabolic inhibitors. KEAP1 mutations enhance resistance to oxidative stress by stimulating glutathione biosynthesis but induce dependence on glutaminase to supply precursors to produce glutathione. Cells are color-coded according to their genotype.